A detailed history of Advisors Asset Management, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 1,992 shares of NTLA stock, worth $23,226. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,992
Previous 2,357 15.49%
Holding current value
$23,226
Previous $52,000 23.08%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$19.72 - $27.36 $7,197 - $9,986
-365 Reduced 15.49%
1,992 $40,000
Q2 2024

Aug 14, 2024

SELL
$20.02 - $27.22 $26,806 - $36,447
-1,339 Reduced 36.23%
2,357 $52,000
Q1 2024

May 14, 2024

SELL
$23.82 - $32.8 $6,169 - $8,495
-259 Reduced 6.55%
3,696 $101,000
Q4 2023

Feb 14, 2024

SELL
$23.16 - $32.34 $17,624 - $24,610
-761 Reduced 16.14%
3,955 $120,000
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $71,234 - $94,821
-2,060 Reduced 30.4%
4,716 $192,000
Q1 2023

May 12, 2023

BUY
$33.3 - $44.82 $5,094 - $6,857
153 Added 2.31%
6,776 $252,000
Q3 2022

Nov 08, 2022

SELL
$53.92 - $71.7 $16,769 - $22,298
-311 Reduced 6.65%
4,366 $244,000
Q2 2022

Aug 08, 2022

BUY
$38.49 - $76.21 $35,795 - $70,875
930 Added 24.82%
4,677 $242,000
Q1 2022

May 17, 2022

SELL
$58.27 - $118.99 $15,033 - $30,699
-258 Reduced 6.44%
3,747 $272,000
Q4 2021

Feb 15, 2022

BUY
$100.76 - $138.36 $56,929 - $78,173
565 Added 16.42%
4,005 $474,000
Q3 2021

Nov 12, 2021

BUY
$132.37 - $176.78 $109,337 - $146,020
826 Added 31.6%
3,440 $461,000
Q2 2021

Jul 30, 2021

BUY
$60.88 - $161.91 $149,886 - $398,622
2,462 Added 1619.74%
2,614 $423,000
Q1 2021

May 07, 2021

BUY
$46.59 - $83.68 $7,081 - $12,719
152 New
152 $12,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $886M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.